HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Mothaffar F. Rimawi, Laia Paré et al.|JNCI Journal of the National Cancer Institute|2019Cited by 168
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F. Rimawi, Rachel Schiff, Carmine De Angelis et al.|Breast Cancer Research and Treatment|2017Cited by 95
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerJamunarani Veeraraghavan, Rachel Schiff, Carmine De Angelis et al.|Annals of Oncology|2019Cited by 42
Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patientsAlejandro Contreras, MF Rimawi, Sabrina Herrera et al.|Cancer Research|2013Cited by 18